Changes in survival in de novo metastatic cancer in an era of new medicines.

ABSTRACT:

Background

Over the past decades, the therapeutic landscape has markedly changed for patients with metastatic solid cancer, yet few studies have evaluated its effect on population-based survival. The objective of this study was to evaluate the change in survival of patients with de novo metastatic solid cancers during the last 30 years.

Methods

For this retrospective study, data from almost 2 million patients diagnosed with a solid cancer between January 1, 1989, and December 31, 2018, were obtained from the Netherlands Cancer Registry, with follow-up until January 31, 2021. We classified patients as with or without de novo metastatic disease (M1 or M0, respectively) at diagnosis and determined the proportion with M1 disease over time. Changes in age-standardized net surviva

SUBMITTER: Luyendijk M 

PROVIDER: S-EPMC10248844 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature